Product Overview: Nebicip
Nebicip 5mg is a third-generation beta-adrenergic receptor antagonist containing nebivolol hydrochloride as the active pharmaceutical ingredient. This selective β1-adrenoreceptor blocker demonstrates unique vasodilatory properties through nitric oxide-mediated mechanisms, distinguishing it from conventional beta-blocking compounds. Manufactured by Cipla under stringent pharmaceutical protocols, each tablet delivers precisely 5mg of nebivolol for consistent research outcomes. The compound exhibits high selectivity for β1-adrenergic receptors while maintaining endothelial nitric oxide synthase activation properties that researchers frequently investigate in cardiovascular physiology studies.
Laboratory Applications
Research scientists utilise Nebicip to examine beta-adrenergic pathway modulation and cardiovascular response mechanisms in controlled laboratory environments. The compound serves as an essential research tool for investigating selective beta-blockade effects combined with endothelium-dependent vasodilation pathways. Cardiovascular research teams frequently analyse this compound’s dual mechanism of action, studying both its beta-blocking properties and its unique ability to enhance nitric oxide bioavailability. Researchers at Stroid UK Shop appreciate its pharmaceutical-grade quality for advanced laboratory protocols. Academic institutions investigating nebivolol mechanisms rely on this compound’s consistent potency. Studies examining metabolic pathways often compare nebivolol’s effects alongside SARM compounds and research peptides to understand comprehensive physiological responses.
Compound Specifications
| Parameter | Specification |
|---|---|
| Active Ingredient | Nebivolol Hydrochloride |
| Strength | 5mg per tablet |
| Manufacturer | Cipla Limited |
| CAS Number | 152520-56-4 |
| Molecular Formula | C₂₂H₂₅F₂NO₄·HCl |
| Molecular Weight | 441.9 g/mol |
| Storage Conditions | Room temperature, dry environment |
| Shelf Life | As per manufacturer specifications |
Research Compliance
This pharmaceutical-grade nebivolol compound is supplied exclusively for in-vitro research purposes and laboratory analysis. Nebicip 5mg is intended solely for qualified researchers conducting cardiovascular studies, receptor binding assays, and pharmacological investigations in controlled laboratory settings. This product is not approved for human consumption, therapeutic use, or any clinical applications outside of research environments. Researchers must ensure proper handling protocols and maintain appropriate documentation for all laboratory studies involving this compound.
